Pacira BioSciences, Inc.PCRXNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank71
3Y CAGR-6.0%
Studio
Year-over-Year Change

Year-over-year research & development expense growth

3Y CAGR
-6.0%/yr
Annual compound
Percentile
P71
Within normal range
vs 3Y Ago
0.8x
Contraction
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
202543.81%
20246.98%
2023-10.07%
202252.66%
2021-6.52%
2020-17.61%
201929.51%
2018-2.80%
201725.42%
201659.37%